<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ACEBUTOLOL HYDROCHLORIDE</span><br/>(a-se-byoo-toe'lole)<br/><span class="topboxtradename">Monitan <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Sectral<br/></span><b>Classifications:</b> <span class="classification"> autonomic nervous system agent</span>; <span class="classification">beta-adrenergic antagonist (blocking agent, sympatholytic)</span>; <span class="classification">cardiovascular agent</span>; <span class="classification">antihypertensive</span>; <span class="classification">antiarrhythmic, class ii agent</span><br/><b>Prototype: </b>Propranolol<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg, 400 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Beta<sub>1</sub>-selective adrenergic blocking agent with mild intrinsic sympathomimetic activity (partial beta-agonist activity). Exhibits
         antiarrhythmic activity (class II antiarrhythmic agent). Produces negative chronotropic and inotropic activity (i.e., decreases
         exercise-induced heart rate, inhibits reflex orthostatic tachycardia, and decreases cardiac output at rest and during exercise).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Decreases both systolic and diastolic BP at rest and during exercise.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of mild to moderate hypertension. Management of recurrent stable ventricular arrhythmias.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Supraventricular arrhythmias, chronic stable angina pectoris.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Overt CHF, second- or third-degree AV block, severe bradycardia, cardiogenic shock; lactation; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired cardiac function, well-compensated CHF, mesenteric or peripheral vascular disease; patients undergoing major surgery
         involving general anesthesia; renal or hepatic impairment; labile diabetes mellitus; hyperthyroidism; bronchospastic disease
         (asthma, emphysema); avoid abrupt withdrawal; pregnancy (category B).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400800 mg/d in 12 divided doses (max: 1200 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 200400 mg/d (max: 800 mg/d)<br/><br/><span class="indicationtitle">Ventricular Arrhythmias</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg b.i.d. increased to 6001200 mg/d<br/><br/><span class="indicationtitle">Angina Pectoris</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300400 mg t.i.d.<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Check apical pulse before administration. If 
         </li><li>Discontinue gradually over a period of 2 wk.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fatigue</span>. <span class="typehead">CNS:</span> Dizziness, insomnia, drowsiness, confusion, fainting. <span class="typehead">CV:</span>
<span class="speceff-common">Bradycardia</span>, hypotension, CHF. <span class="typehead">GI:</span> Nausea, <span class="speceff-common">diarrhea, constipation,</span> flatulence. <span class="typehead">Hematologic:</span> Agranulocytosis, <span class="speceff-common">antinuclear antibodies (ANA).</span>
<span class="typehead">Metabolic:</span> hypoglycemia (may mask symptoms of a hypoglycemic reaction). <span class="typehead">Respiratory:</span> Bronchospasm, pulmonary edema, dyspnea. <span class="typehead">Urogenital:</span> Decreased libido; impotence. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>False-negative test results possible (see <b>propranolol</b>).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Other <span class="classification">hypotensive agents</span>, <span class="classification">diuretics</span> increase hypotensive effect; with <b>albuterol,</b>
<b>metaproterenol,</b>
<b>terbutaline,</b> or <b>pirbuterol,</b> there is mutual antagonism with acebutolol; <span class="classification">nsaid</span>s blunt hypotensive effect; decreases hypoglycemic effect of <b>glyburide;</b> increases bradycardia and sinus arrest with <b>amiodarone</b>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed after PO administration; undergoes extensive first-pass metabolism in liver with an average bioavailability
      of 40%. (In geriatric patients, bioavailability increases twofold). <span class="typehead">Peak:</span> 3 h. <span class="typehead">Distribution:</span> Minimally into CSF; crosses placenta; is excreted in breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to diacetolol with activity equipotent to parent compound. <span class="typehead">Elimination:</span> Metabolite 813 h; 5060% excreted via bile into feces, and 3040% excreted in urine. <span class="typehead">Half-Life:</span> 34 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP and cardiac status throughout therapy. Observe for and report marked bradycardia or hypotension, especially when
            patient is also receiving a catecholamine-depleting drug (e.g., reserpine).
         </li>
<li>Monitor I&amp;O ratio and pattern and report changes to physician (e.g., dysuria, nocturia, oliguria, weight change).</li>
<li>Monitor for S&amp;S of CHF, especially peripheral edema, dyspnea, activity intolerance.</li>
<li>Lab tests: Monitor for drug-induced positive ANA titer during long-term therapy, especially in women and older adults; periodic
            CBC with long-term therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Know parameters for withholding drug (e.g., pulse less than 60).</li>
<li>
            							Note: Common adverse effects include insomnia, drowsiness, and confusion.
            						
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not increase, decrease, omit, or discontinue drug regimen without advice from the physician. Abrupt withdrawal may worsen
            angina or precipitate MI in patient with heart disease.
         </li>
<li>Contact physician promptly at the first signs or symptoms of CHF (see Appendix F).</li>
<li>Report muscle and joint pain to physician. Discontinuation of drug therapy usually reverses these adverse effects.</li>
<li>Monitor for loss of glycemic control if diabetic.</li>
<li>
            							Note: Drug may mask symptoms of hypoglycemia (see Appendix F) and potentiate insulin-induced hypoglycemia in diabetics.
            						
         </li>
<li>Avoid use of OTC oral cold preparations and topical nasal decongestants unless approved by the physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>